Science
PRECISION BIOLOGICS
Multimodal Innovation for Life-Changing Therapies
At Fortvita Biologics, we integrate cutting-edge biotechnology across multiple modalities to accelerate therapeutic innovation. Our platform is built on three key pillars: established technologies such as next-generation antibodies and antibody-drug conjugates (ADCs); emerging modalities including siRNA, bi-specific degraders (RDC), small molecule degraders, mRNA cancer vaccines, and cyclic peptides; and future advancements in cell and gene therapy.
At the core of this platform is a robust antibody engineering engine that enables the creation of novel therapeutic constructs. These include variable heavy-chain (VHH) antibody platforms designed for highly specific antigen targeting, as well as multi-specific T cell engager (TCE) platforms designed to harness and direct the immune system against tumors. Together, these capabilities position Fortvita at the forefront of next-generation biologics development.
IMMUNO-ONCOLOGY & ADC SYNERGY
Powered by Antibody Engineering Talent & Innovation
A core pillar of Fortvita’s strategy is the synergy between Immuno-Oncology (IO) and Antibody-Drug Conjugates (ADC) to transform cancer treatment. Our oncology platform integrates advanced IO capabilities with proprietary linker-payload technologies, including our topoisomerase 1 inhibitor (TOPO1i) platform, engineered to enhance the potency and precision of ADC therapies.
Supported by a world-class R&D team of scientists and a robust foundation in preclinical and clinical research, Fortvita is deepening its leadership in oncology while extending its technological innovation to other high-impact therapeutic areas—cardiovascular and metabolic medicine (CVM), autoimmune diseases, and ophthalmology. Each of these areas leverages our antibody engineering expertise to drive the development of targeted, next-generation therapies.